Immunohematology Market: Advancements in Blood Typing and Laboratory Automation Strengthen Transfusion Safety

Market Estimation, Growth Drivers and Opportunities

The global Immunohematology Market was valued at USD 2.79 billion in 2025 and is projected to reach approximately USD 3.97 billion by 2034, registering a CAGR of 4% during 2026–2034, according to Maximize Market Research. Immunohematology plays an essential role in transfusion medicine by identifying blood groups, detecting red blood cell antibodies and establishing compatibility between blood donors and recipients. Growing demand for safe blood transfusions, increasing prevalence of blood-related disorders and expansion of diagnostic laboratory infrastructure are supporting market development.

Rising cases of cancer, sickle cell disease, thalassemia and other conditions requiring repeated transfusions are increasing demand for accurate blood typing and compatibility testing. Growth in surgical procedures, trauma care and maternal healthcare is also strengthening the need for reliable immunohematology services. Hospitals and blood banks are increasingly adopting automated analysers, advanced reagents and digital laboratory systems to reduce manual errors and improve testing efficiency. Opportunities are emerging through molecular blood group genotyping, automated antibody screening, laboratory information system integration and high-throughput testing platforms. However, expensive diagnostic equipment, reagent costs and shortages of trained laboratory professionals may restrict adoption in smaller healthcare facilities.

* Stay Ahead of Industry Trends: https://www.maximizemarketresearch.com/request-sample/33950/ 

US Market Trends and Investment

The United States is an important market for immunohematology because of its established blood banking infrastructure, advanced diagnostic capabilities and high demand for transfusion safety. A significant development occurred on October 16, 2025, when Grifols began manufacturing its DG Gel cards and reagent red blood cells at its expanded 73,541-square-foot facility in San Diego, California, following FDA approvals. The facility nearly doubles the company's campus footprint and strengthens domestic production of products used in blood typing and pre-transfusion compatibility testing. In September 2025, Bio-Rad showcased its IH-500 Next automated blood bank analyser and updated quality-control reagents at the IBMS Congress, highlighting improvements in laboratory workflow and testing flexibility. The FDA also cleared Immucor's ImmuLINK blood establishment computer software in October 2025. These developments reflect increasing investment in domestic manufacturing, laboratory automation and digital transfusion medicine systems.

Market Segmentation: Leading Segment

By product, immunohematology reagents are expected to dominate the market during the forecast period, according to MMR. Reagents are essential for blood grouping, antibody screening, antigen identification and compatibility testing. Their recurring use across blood banks, hospitals and diagnostic laboratories generates consistent demand. Increasing adoption of automated testing platforms and the need for reliable transfusion results are further supporting this segment. The growing requirement for specialised reagents and customised testing solutions is expected to strengthen its position.

Immunohematology Market Key Players
1.Bio-Rad Laboratories, Inc.
2.Immucor
3.Grifols
4.BD (Becton Dickinson)
5.Hologic, Inc.
6.Siemens Healthcare GmbH
7.ThermoFisher
8.Abbott
9.Beckman Coulter, Inc.
10.Ortho Clinical Diagnostics
11.Roche Diagnostics Corporation
12.Merck KGaA
13.Cardinal Health Inc.
14.CSL Ltd.
15.Danaher Corp.
16.MTC Invitro Diagnostics AG
17.F. Hoffmann-La Roche Ltd.
18.Antisel

Competitive Analysis

The MMR report identifies several major companies operating in the global Immunohematology Market. Five prominent participants include:

Bio-Rad Laboratories, Inc.: Bio-Rad continues to strengthen automated blood bank testing through its IH-500 platform. At the 2025 IBMS Congress, the company presented the IH-500 Next System with enhanced software and greater workflow flexibility, alongside updated independent quality-control reagents. Its automation technology supports blood grouping, antibody screening and laboratory data management.

Immucor, Inc.: Immucor focuses on automated blood bank testing and transfusion medicine software. In October 2025, the FDA cleared its ImmuLINK blood establishment computer software, supporting digital management of blood establishment information. Its Echo and Erytra-compatible product ecosystem addresses laboratory automation and transfusion testing requirements.

Grifols: Grifols expanded its US immunohematology manufacturing capabilities in October 2025 by beginning production of DG Gel cards and reagent red blood cells at its San Diego facility. The company also received FDA clearance for its Erytra automated blood grouping and antibody testing system in June 2025, strengthening its portfolio of transfusion medicine technologies.

BD (Becton, Dickinson and Company): BD contributes to the wider blood diagnostics ecosystem through blood collection systems, specimen management and laboratory technologies. Its Vacutainer portfolio supports standardised blood collection and sample handling, which are important components of reliable diagnostic workflows.

Ortho Clinical Diagnostics: Ortho's automated blood bank testing portfolio includes ORTHO VISION and VISION Max analysers, which use ID-MTS gel card technology for blood grouping and antibody testing. In October 2025, the FDA listed these systems in its device approvals, reinforcing the role of automated platforms in transfusion testing.

These companies are identified in the MMR report's competitive landscape. The report does not publish verified individual market-share percentages or a definitive ranking of the five largest companies.

Regional Analysis

United States: North America is projected to dominate the global market, supported by advanced healthcare infrastructure, established blood banks, skilled professionals and early adoption of automated diagnostic technologies. FDA oversight and investments in domestic manufacturing strengthen the market.

United Kingdom: The NHS blood and transplant system and established transfusion safety requirements support demand for reliable blood typing, antibody screening and diagnostic reagents.

Germany: Strong hospital infrastructure, diagnostic laboratory capabilities and European blood safety standards support adoption of advanced immunohematology equipment.

France: Established transfusion services and European Union quality and safety requirements create demand for reliable testing systems. The EU's Regulation on Substances of Human Origin, which applies mainly from August 2027, is expected to strengthen quality and safety standards.

Japan: An established healthcare system, ageing population and government emphasis on safe blood supply support demand for accurate transfusion testing and laboratory technologies.

China: Government regulation of blood stations, mandatory testing and quality-control requirements support investment in blood banking and diagnostic infrastructure. The country's large healthcare system also creates demand for reliable blood compatibility testing.

Conclusion

The Immunohematology Market is expected to maintain steady growth as healthcare providers prioritise transfusion safety, diagnostic accuracy and efficient blood bank operations. Automated analysers, advanced reagents, molecular blood group testing and digital laboratory integration will create important opportunities. Manufacturers that invest in reliable testing technologies, domestic production and scalable automation solutions are likely to strengthen their competitive positions. Increasing transfusion requirements and the need for improved compatibility testing will remain major factors supporting long-term market development.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com